Groutz A, Blaivas J G, Kesler S S, Weiss J P, Chaikin D C
Weill Medical College, Cornell University, New York, New York, USA.
J Urol. 2000 Dec;164(6):2006-9.
We assessed the results of collagen injection for female sphincteric incontinence using strict subjective and objective criteria.
We evaluated 63 consecutive women with sphincteric incontinence who underwent a total of 131 transurethral collagen injections. Sphincteric incontinence was confirmed by urodynamics. All patients were treated with 1 to 5 transurethral collagen injections and treatment outcome was classified according to a new outcome score. Cure was defined as no urinary loss due to urge or stress incontinence documented by a 24-hour diary and pad test, and patient assessment that cure was achieved. Failure was defined as poor objective results and patient assessment that treatment failed. Cases that did not fulfill these cure and failure criteria were considered improved and further classified as a good, fair or poor response.
Mean patient age plus or minus standard deviation was 67.7 +/- 12.8 years. All women had a long history of severe stress urinary incontinence, 18 (29%) underwent previous anti-incontinence surgery, and 41% had combined stress and urge incontinence. Preoperatively diary and pad tests revealed a mean of 7.5 +/- 4.6 incontinence episodes and 152 +/- 172 gm. of urine lost per 24 hours. Overall 1 to 5 injections were given in 26, 17, 13, 3 and 4 patients, respectively. Mean interval between injections was 4.4 +/- 5.7 months, mean followup was 12 +/- 9.6 months, and mean interval between the final injection and outcome assessment was 6.4 +/- 4.9 months. There was a statistically significant decrease in the total number of incontinence episodes per 24-hour voiding diary after each injection session. Although there was a clear trend toward decreased urinary loss per 24-hour pad test, statistical significance was not established. Using the strict criteria of our outcome score overall 13% of procedures were classified as cure, 10%, 17% and 42% as good, fair and poor, respectively, and 18% as failure.
As defined by strict subjective and objective criteria, we noted a low short-term cure rate after collagen injection in women with severe sphincteric incontinence. It remains to be determined how patients with less severe incontinence would fare using our outcome assessment instruments.
我们使用严格的主观和客观标准评估了胶原蛋白注射治疗女性括约肌性尿失禁的效果。
我们评估了63例连续性括约肌性尿失禁女性患者,她们总共接受了131次经尿道胶原蛋白注射。通过尿动力学检查确诊为括约肌性尿失禁。所有患者接受1至5次经尿道胶原蛋白注射治疗,并根据一种新的疗效评分对治疗结果进行分类。治愈定义为24小时排尿日记和护垫试验未记录到因急迫性或压力性尿失禁导致的尿液丢失,且患者评估已治愈。失败定义为客观结果不佳且患者评估治疗失败。未达到这些治愈和失败标准的病例被视为改善,并进一步分为良好、一般或差的反应。
患者的平均年龄±标准差为67.7±12.8岁。所有女性均有严重压力性尿失禁的长期病史,18例(占29%)曾接受过抗尿失禁手术,41%同时存在压力性和急迫性尿失禁。术前排尿日记和护垫试验显示,平均失禁发作次数为7.5±4.6次,每24小时尿液丢失量为152±172克。总体而言,分别有26例、17例、13例、3例和4例患者接受了1至5次注射。注射之间的平均间隔时间为4.4±5.7个月,平均随访时间为12±9.6个月,最后一次注射与疗效评估之间的平均间隔时间为6.4±4.9个月。每次注射后,24小时排尿日记中失禁发作的总数有统计学意义的下降。尽管每24小时护垫试验中尿液丢失量有明显下降趋势,但未达到统计学意义。根据我们严格的疗效评分标准,总体上13%的治疗被分类为治愈,10%、17%和42%分别为良好、一般和差,18%为失败。
按照严格的主观和客观标准定义,我们发现严重括约肌性尿失禁女性患者胶原蛋白注射后的短期治愈率较低。对于失禁程度较轻的患者使用我们的疗效评估工具的效果仍有待确定。